ANNEXURE I

Format to be submitted by listed entity on quarterly basis

 Name of Listed Entity
 Quarter ending - %SMS Pharmaceuticals% - %31-03-2020%

Composition Of Board Of Director i.

T i t l e (M r ./ M s)	Na me of the Dir ect or	0-2	ΑZ	Cat ego ry (Ch airp ers on /Exe cutiv e/No n- Exec utive/ Inde pend ent/ Nomi nee)	Sub Category	Initia I D at e of A p p oi nt m e nt	Dat e of App oint me nt	Dat e of ces sati on	T e n ur e	D at e of Bi rt h	Whether special resolution passed?	Date of passings pecial resolution	No. of Directors hip in listed entities in cluding this listed entity	No of Indepe ndent Direct orship in listed entitie s includi ng this listed entity	No f mb ers s hip in A dit/s kehd er o m tet e(s) cl di g is st de enty	No foot of Cair person in A dit/Sakeholder Committeehold in list dentities in Linguistria entity	Me mbe rshi p in Co mmi ttee s of the Co mpa ny	Remarks
r.	me sh Ba bu Pot luri	0 1 6 6 3 8	D F P P	ED		Au g- 199 0	Aug- 1990		U	3- Ju n- 1 9	IVA			U	2	U	,NRC	

		1 1					9							
		4 C												
M r.	TV VS N Mu rth y	0 A 0 B 4 K 6 P 5 T 1 0 9 2 8 5 5 F	NED	30- Au g- 199 0	30- Aug- 1990	0	1 0- F eb - 1 9 6	NA	2	0	2	0	SC,NR C	
M r.	Pak ala pati Sar ath Ku mar	0 A 1 D 4 F 5 P 6 P 7 2 4 2 6 9 2 P	ID	30- Sep - 201 4	30- Sep- 2014	6 0	1 5- A u g- 1 9 5 7	NA	2	2	2	2	SC	
M r.	shr ava n Ku dar ava lli	0 A 6 A 9 Z 0 P 5 K 8 5 5 4 1 7 3 C	ID	20- Sep - 201 8	20- Sep- 2018	6 0	2 8- A pr - 1 9 7 8	NA	2	2	2	1	AC,N RC	
M r.	Sar vep alli Sri niv as	0 A 2 K 2 IP 9 S 2 7 0 6 5 9 1 2 B	ID	12- Au g- 201 9	12- Aug- 2019		2 9- Ju n- 1 9 6 2	NA	1	1	1	0	SC	
M rs	Th um mal a Ne ela ven i	0 A 0 C 0 D 6 P 5 T 5 0 7 3 1 0	ID	30- Sep - 201 4	30- Sep- 2014	6 0	0 1- Ju 1- 1 9 6 3	NA	2	2	4	1	AC,SC ,NRC	

			0											
			K											
M	Shi	0	A	NED	31-	31-	0	0	NA	1	0	0	0	
rs	lpa	7	A	,ND	Jan	Jan-		1-						
	R	0	N		-	2019		Ju						
	Wa	0	P		201			1-						
	gh	9	W		9			1						
	mar	9	7					9						
	e	6	7					7						
		6	6					2						
			8											
			C											

Company Remarks	
Whether Permanent	Yes
chairperson appointed	
Whether Chairperson is	Yes
related to MD or CEO	

ii. Composition of Committees

a. Audit Committee

Sr. No.	Name of the Director	Category	Chairperson/Membership	Appointment Date	Cessation Date
1	shravan Kudaravalli	ID	Chairperson	26-May-2018	
2	Thummala Neelaveni	ID	Member	30-Sep-2014	
3	Ramesh Babu Potluri	C & ED	Member	12-Aug-2019	

Company Remarks	
Whether Permanent	Yes
chairperson appointed	

b. Stakeholders Relationship Committee

Sr.	Name of the Director	Category	Chairperson/Membership	Appointment	Cessation Date
No.				Date	
1	Pakalapati Sarath Kumar	ID	Chairperson	30-Sep-2014	
2	Thummala Neelaveni	ID	Member	30-Sep-2014	
3	Sarvepalli Srinivas	ID	Member	12-Aug-2019	
4	Ramesh Babu Potluri	C & ED	Member	12-Aug-2019	
5	TVVSN Murthy	NED	Member	12-Aug-2019	

Company Remarks	
Whether Permanent	Yes
chairperson appointed	

c. Risk Management Committee

Sr.	Name of the Director	Category	Chairperson/Membership	Appointment	Cessation Date
No.				Date	

Company Remarks	
Whether Permanent	

chairperson appointed	

d. Nomination and Remuneration Committee

Sr.	Name of the Director	Category	Chairperson/Membership	Appointment	Cessation Date
No.				Date	
1	Thummala Neelaveni	ID	Chairperson	30-Sep-2014	
2	shravan Kudaravalli	ID	Member	12-Aug-2019	
3	Ramesh Babu Potluri	C & ED	Member	12-Aug-2019	
4	TVVSN Murthy	NED	Member	12-Aug-2019	

Company Remarks	
Whether Permanent	Yes
chairperson appointed	

iii. Meeting of Board of Directors

Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Whether requirement of Quorum met	Number of Directors present	Number of Independent Directors present
	12-Feb-2020	Yes	7	4
	18-Mar-2020	Yes	6	4

Company Remarks	
Maximum gap between any	0
two consecutive (in number of	
days)	

iv. Meeting of Committees

Name of the Committee	Date(s) of meeting during of the committee in the previous quarter	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Number of Directors present	Number of independent directors present
Audit Committee	12-Nov-2019		Yes	3	2
Audit Committee		12-Feb-2020	Yes	3	2
Nomination &		18-Mar-2020	Yes	4	2
Remuneration					
Committee					

Company Remarks	
Maximum gap between any	91
two consecutive (in number of	
days) [Only for Audit	
Committee]	

v. Related Party Transactions

Subject	Compliance status (Yes/No/NA)	Remark
Whether prior approval of audit committee obtained	Yes	
Whether shareholder approval obtained for material RPT	Not Applicable	

Whether details of RPT entered into p approval have been reviewed by Audi		Not Applicable	
approval have been reviewed by Audi	t Committee		
Disclosure of notes on related			
party transactions and			
Disclosure of notes of material			
related party transactions			

VI. Affirmations

- The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - Yes
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee Yes
 - b. Nomination & remuneration committee Yes
 - c. Stakeholders relationship committee Yes
 - d. Risk management committee (applicable to the top 100 listed entities) Not applicable
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes
- The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.-Yes
- 5. a. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Yes
 - b. Any comments/observations/advice of Board of Directors may be mentioned here:

%affirmComments%

Name : %affirmName%

Designation : %affirmDesignation%

ANNEXURE II

Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)

I. Disclosure on website in terms of Listing Regulations						
Item	Со	mplianc	Compai	ny Remark	W	/ebsite
	es	tatus	1	<i>J</i>		
As per regulation 46(2) of the LODR:						
Details of business	Yes				ww	/w.smspharma.com
Terms and conditions of appointment of	Yes					w.smspharma.com
Composition of various committees of	Yes					w.smspharma.com
Code of conduct of board of directors and	Yes					/w.smspharma.com
Details of establishment of vigil mechanism/						w.smspharma.com
Criteria of making payments to non-	Not					W.Smspharma.com
Policy on dealing with related party	Yes				١٨/١٨	w.smspharma.com
Policy for determining 'material' subsidiaries					000	W.Smspharma.com
Details of familiarization programs imparted					14/14	w.smspharma.com
						w.smspharma.com
other relevant details entity who are	Yes				"	· ···. Jili Jpharina.com
Contact information of the designated	Yes				W/\^	w.smspharma.com
Financial results	Yes					w.smspharma.com
Shareholding pattern	Yes					w.smspharma.com
Details of agreements entered into with the	Not					
media companies and/or their associates		licable				
Schedule of analyst or institutional investor	Not	ilcabic				
meet and presentations madeby the listed		licable				
New name and the old name of the listed	Not	iloabic				
Advertisements as per regulation 47 (1)					ww	w.smspharma.com
Credit rating or revision in credit rating	Not					W.Smspharma.com
Separate audited financial statements of	Not					
As per other regulations of the LODR:						
Whether company has provided information	Not					
under separate section on its website as		licable				
per Regulation 46(2)	, , , pp	iloabio				
Materiality Policy as per Regulation 30	Yes				ww	w.smspharma.com
Dividend Distribution policy as per	Not					
It is certified that these contents on the	Yes				ww	w.smspharma.com
II Annual Affirmations						
Particulars		Regulati	on	Compl		Company
		Number		iance		Remark
La deve en de set d'accetente à la contra de la contra del la contra de la contra del la contra de la contra del la contra de la contra del la contra de la contra del la contra de la contra de la contra del la contra del la co		40/41/11	0.05/0\	status		,
Independent director(s) have been		16(1)(b)	& 25(6)	Voc		
appointed in terms of specified criteria of 'independence' and/or 'eligibility'				Yes		
Board composition		17/1\ 47	7/1/1/ 0			
,		17(1), 17 17(1B)	(<i>1A)</i> &	Yes		
Meeting of Board of directors		17(2)		Yes		
Quorum of Board meeting		17(2A)		Yes		
Review of Compliance Reports		17(3)		Yes		
Plans for orderly succession for		17(4)		Yes		
appointments						
Code of Conduct		17(5)		Yes		

Fees/compensation	17(6)	Not Applicable
Minimum Information	17(7)	Yes
Compliance Certificate	17(8)	Yes
Risk Assessment & Management	17(9)	Yes
Performance Evaluation of Independent	17(10)	Yes
Directors	()	l'es
Recommendation of Board	17(11)	Yes
Maximum number of directorship	17A	Yes
Composition of Audit Committee	18(1)	Yes
Meeting of Audit Committee	18(2)	
Composition of nomination & remuneration	19(1) & (2)	Yes
committee	19(1) & (2)	Yes
Quorum of Nomination and Remuneration		Yes
Committee meeting	19(2A)	
Meeting of nomination & remuneration		Yes
committee	19(3A)	
Composition of Stakeholder Relationship	20(1), 20(2) and	Yes
Committee	20(2A)	
Meeting of stakeholder relationship		Yes
committee	20(3A)	
Composition and role of risk management committee	21(1),(2),(3),(4)	Not Applicable
Meeting of Risk Management Committee		Not Applicable
	22	100 Applicable
Vigil Mechanism	22	Yes
Policy for related party Transaction	23(1),(1A),(5),(6	Yes
Prior or Omnibus approval of Audit	23(2), (3)	Yes
Committee for all related party	(-), (-)	
Approval for material related party	23(4)	Not Applicable
transactions	()	
Disclosure of related party transactions on	23(9)	Not Applicable
consolidated basis		
Composition of Board of Directors of	24(1)	Not Applicable
unlisted material Subsidiary		
Other Corporate Governance	24(2),(3),(4),(5)	Not Applicable
requirements with respect to subsidiary of	& (6)	
Annual Secretarial Compliance Report		Yes
	24(A)	
Alternate Director to Independent Director	25(1)	Not Applicable
Maximum Tenure		Vos
Waxiiiaiii Tollaio	25(2)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Declaration from Independent Director	25(8) & (9)	Yes
D & O Insurance for Independent	25(10)	Yes
Memberships in Committees	26(1)	
Affirmation with compliance to code of	26(3)	Yes
conduct from members of Board of	20(3)	
Directors and Senior management		Yes
personnel		
Disclosure of Shareholding by Non-	26(4)	Yes
Executive Directors	1 - 5(.)	103

directors and senior management	Policy with respect to Obligations of	26(2) & 26(5)	Yes	
	directors and senior management			

Other Information	
Other information	

III Affirmations:

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied. **- Not Applicable**

Other Information	

Name : Ramesh Babu potluri Designation : Managing Director